Natco Pharma to Launch Generic Semaglutide in India This March
Natco Pharma Ltd. has received government approval to manufacture and market its generic Semaglutide injection in India. The company plans to launch the product in March 2026, according to a statement released on Saturday.
What is Semaglutide?
Semaglutide is a prescription medicine used to treat adults with type 2 diabetes that is not well-controlled. It is used alongside diet and exercise to improve blood sugar levels.
The approval was granted by the Central Drugs Standard Control Organisation (CDSCO), which operates under the Ministry of Health and Family Welfare.
How the Medication Works
Semaglutide belongs to a class of drugs known as GLP-1 receptor agonists. It works by helping the pancreas release the right amount of insulin when blood sugar levels are high. This insulin then signals muscle and fat cells to absorb glucose, which the body uses for energy.
In the U.S., this medication is sold under the brand names Ozempic, Wegovy, and Rybelsus. While all three brands are already available in India, Natco’s version will offer a more accessible generic option.
Market Strategy and Growth
Natco Pharma expects the Indian market for Semaglutide to be highly competitive. During a recent earnings call, executives mentioned that the company will launch its own brand while also licensing the drug to two other companies.
To support this launch, Natco has shared the following plans:
- Target Growth: The company expects Semaglutide to drive its domestic business, targeting more than 20% growth.
- Sales Support: Approximately 350 to 400 medical representatives will focus on promoting the drug.
- International Advantage: In the U.S., Natco holds “First-To-File” (FTF) exclusivity for certain strengths of both Ozempic and Wegovy, giving it a strong competitive edge in the global market.
Stock Market Reaction
Following the news, shares of Natco Pharma closed at Rs 822.10 on Friday, down 2.1%. This move occurred during a general market dip, as the benchmark BSE Sensex fell by 1.25%.
Also Read : Dixon Tech Finalizes Joint Venture with Longcheer for Smartphone Manufacturing
